Different behaviour of soluble CD40L concentrations can be reflected by variations of preanalytical conditions

Clinical Hemorheology and Microcirculation

Volumn 39, Issue 1-4, 2008, Pages 417-422

  Wenzel, F ^a   Baertl, A ^b   Zimmermann, N ^c   Hohlfeld, Th ^d   Giers, G ^b   Oldenburg, J ^e   Assert, R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Federal Institute for Drugs and Medical Devices Bundesinstitut für Arzneimittel und Medizinprodukte   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Platelet count; Preanalytical conditions; Serum samples; Soluble CD40L

Indexed keywords

CD40 LIGAND; CITRIC ACID; EDETIC ACID; SOLUBLE CD40 LIGAND;

ADULT; BLOOD DONOR; BLOOD SAMPLING; CONFERENCE PAPER; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NORMAL HUMAN; STORAGE; THROMBOCYTE COUNT; THROMBOCYTE RICH PLASMA;

ADULT; BIOLOGICAL MARKERS; BLOOD PLATELETS; CD40 LIGAND; CITRIC ACID; EDETIC ACID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNE SYSTEM; INFLAMMATION; MALE; PLATELET COUNT; SOLUBILITY; TIME FACTORS;

EID: 47849126202     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: 10.3233/CH-2008-1112     Document Type: Conference Paper

References (13)

1. P. Aukrust, F. Muller, T. Ueland, T. Berget, E. Aaser, A. Brunsvig, N.O. Solum, K. Forfang, S.S. Froland and L. Gullestad, Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes, Circulation 10 (1999), 614-620.
2. P. Aukrust, J.K. Damas and N.O. Solum, Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation?, J. Am. Coll. Cardiol. 16 (2004), 2326-2328.
3. S. Danese, J.A. Katz, S. Saibeni, A. Papa, A. Gasbarrini, M. Vecchi and C. Fiocchi, Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients, Gut 52 (2003), 1435-1441.
4. U. Schonbeck and P. Libby, The CD40/CD154 receptor/ligand dyad, Cell. Mol. Life Sci. 58 (2001), 4-43.
5. C. van Kooten and J. Banchereau, CD40-CD40 ligand, J. Leukoc. Biol. 67 (2000), 2-1
6. V. Henn, S. Steinbach, K. Buchner, P. Presek and R.A. Kroczek, The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40, Blood 15 (2001), 1047-1054.
7. P. Andre, K.S. Prasad, C.V. Denis, M. He, J.M. Papalia, R.O. Hynes, D.R. Phillips and D.D. Wagner, CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism, Nat. Med. 8 (2002), 247-252.
8. E.R. Ahn, G. Lander, W. Jy, C.J. Bidot, J.J. Jimenez, L.L. Horstman and Y.S. Ahn, Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk, Thromb. Res. 114 (2004), 143-148.
9. M. Weber, B. Rabenau, M. Stanisch, A. Elsaesser, V. Mitrovic, C. Heeschen and C. Hamm, Influence of sample type and storage conditions on soluble CD40 ligand assessment, Clin. Chem. 52 (2006), 888-891.
10. N. Varo, R. Nuzzo, C. Natal, P. Libby and U. Schonbeck, Influence of pre-analytical and analytical factors on soluble CD40L measurements, Clin. Sci. 111 (2006), 341-347.
11. I.D. Conde and N.S. Kleiman, Soluble CD40 ligand in acute coronary syndromes, N. Engl. J. Med. 19 (2003), 2575-2577.
12. D. Bereczki, E. Nagy, A. Pal, M.T. Magyar and J. Balla, Should soluble CD40 ligand be measured from serum or plasma samples?, Arterioscler. Thromb. Vasc. Biol. 1 (2003), 1129-1130.
13. V. Henn, S. Steinbach, K. Buchner, P. Presek and R.A. Kroczek, The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40, Blood 15 (2001), 1047-1054.